Oral CD11b Activator for Lupus Nephritis
Official title: Translating oral CD11b agonist as a novel therapeutic for lupus nephritis
Funded at University of Texas Med Br Galveston · NIH-11380829 · Data updated 2026-11-12
A new oral CD11b activating drug is being explored to help people with lupus nephritis by targeting immune pathways that cause kidney inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project start | September 20, 2011 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $713,048 |
| NIH project number | 5R01DK084195-15 |
| Project ID | NIH-11380829 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with lupus nephritis or those with active kidney inflammation due to SLE.
✕Less likely to help
Patients without lupus or those without kidney involvement may not experience direct benefit.
What this research studies
This project focuses on a highly selective CD11b agonist to correct overactive immune signaling seen in lupus nephritis. It builds on findings that certain genetic variants in CD11b are linked to worse kidney inflammation and higher inflammatory mediators. The research aims to determine how activating CD11b can dampen damaging inflammatory signals and protect kidney function in affected patients. The work involves preclinical studies and early investigations of how the drug behaves in the body to guide future human trials.
Why it matters
Potential benefit: If successful, this approach could lead to a targeted therapy that reduces kidney inflammation and preserves kidney function in lupus patients.
How similar studies have gone: Preclinical data suggest CD11b activation can regulate inflammatory pathways relevant to lupus nephritis, with promising signals but not yet proven in humans.
Where this research is happening
-
University of Texas Med Br Galveston
Galveston, United States Active
Researchers
- Principal investigator: Gupta, Vineet — University of Texas Med Br Galveston
- Study coordinator: Gupta, Vineet
Related research
Other NIH-funded projects on the same topics.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
-
Sodium’s effect on kidney B cells in lupus kidney disease
This grant explores how high sodium in the kidneys affects B cells in lupus nephritis and whether blocking a key cellular pump could reduce kidney damage.
-
Objective classification of lupus nephritis using computer vision
A new computer vision tool uses deep learning to classify lupus nephritis from kidney tissue images to help doctors predict outcomes for patients with lupus.
-
AI-powered look at lupus nephritis in humans and mice
Researchers will use artificial intelligence to compare kidney tissue from people with lupus nephritis to tissue from mouse models, aiming to understand why treatments work differently in humans.
-
miR-21 and B cells in lupus: how a tiny molecule can drive autoimmunity
Aims to understand how a microRNA called miR-21 influences B cells and kidney inflammation in lupus, with the goal of finding targeted therapies for people with SLE.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.